Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Global Renal Denervation Market Opportunity Assessment to Reveal Lucrative Growth Prospects for Play

Author: Apurva Deshpande
by Apurva Deshpande
Posted: Jan 11, 2019

FDA Approvals to Foster Demand Growth

Regulatory approvals are becoming a necessary aspect for effective business for the providers of renal denervation offerings. The US Food & Drug Administration (FDA) approval for use of renal denervation systems is a key milestone for the renal denervation market participants. The companies are seeking approval for their renal denervation systems and devices for their use in clinical trials. Medtronic, a leading renal denervation market player announced the FDA approval a clinical trial of the company’s Symplicity Spyral renal denervation system in patients on high blood pressure medications.

Continual Clinical Trials in Emerging Nations to Reflect Future Opportunities for Market Players

The increasing clinical trials for the treatment for disorders such as hypertension and blood pressure are a major influencing factor for the renal denervation market. This rise in trials is expected to boost the consumption of renal denervation thereby offering promising opportunities for market players.

Emerging clinical trials in leading economies such as Europe and the United States are expected to provide scope of development. For instance, Stanford Health, is pioneering the ongoing RADIANCE-HTN study in Connecticut. The international and multicenter trial is connected at various centers located in Europe and the United States. The aim of the study is to examine and investigate the capabilities of endovascular ultrasound-based renal denervation for reducing blood pressure in patients with treatment resistant hypertension or moderate or mild hypertension. The initial data reflected a significant decrease in blood pressure. Stanford recognizes the need for this trial as hypertension affects 1 out of 3 adults in America.

Request sample Report@

New Capabilities of Renal Denervation

Renal Denervation incorporated with ultrasound technology are capable of overcoming the limitations of radiofrequency based renal denervation system. The high-frequency sounds waves of the ultrasound energy help in ablating the nerves, without coming in direct contact with the tissues. This helps in reducing renal arteries injuries.

According to a clinical trial RADIOSOUND-HTN, presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, the ultrasound based ablation of renal arteries reflected superiority over multipolar radiofrequency based ablation, according to investigators.

Ultrasound renal denervation system are gaining major emphasis which is greatly supported by the approvals from regulatory bodies. ReCor medical, for instance, recently announced the approval of Investigational Device Exemption (IDE) for its new pivotal study of Paradise Ultrasound Denervation System for treating hypertension by the FDA.

Competitive Landscape helps in Examining Strategies Adopted by Prominent Players

The prominent players in the renal denervation market are constantly working towards developing a robust systems which could incorporate renal denervation for reducing the challenges related to blood pressure and hypertension. Clinical trials are increasingly being carried out to uplift the capabilities of renal denervation. The key players that contribute to the overall renal denervation market include Medtronic PLC, Symple Surgical, Inc., Cardiosonic, Inc., Boston Scientific Corp., Kona Medical, Inc., ReCor Medical, Inc., Abbott Laboratories, Mercator MedSystems, Inc., Ablative Solutions, Inc., and Renal Dynamics.

Some Developments Carried Out by Renal Denervation Market Players

Otsuka Holdings acquired ReCor Medical, Inc., reflecting a significant step in future for the company’s medical device business, by harnessing an innovative technology with the expertise of Otsuka in clinical and pharmaceuticals development, as stated by the company president.

Abbott Laboratories are greatly engaging in clinical trials for a range of health related issues for providing support to the patients. In line with this, the company recently announced the industry’s only trial for ablation treatment evaluation for a common heart rhythm disorder, ventricular tachycardia (VT), which causes lower chambers of the heart to beat faster than the normal rate.

Mercator MedSystems, Inc., received a Series D funding which would enhance the clinical developments of the company’s micro-infusion catheter systems and expand its vision of bettering the outcomes of patients with pulmonary and cardiovascular disease across the globe.

Request TOC@

Determining Key Segments with Renal Denervation Market Segmentation

The renal denervation market is classified on the basis of product and technology.

On the basis of product, the renal denervation market is segmented into:

  • EnligHTN
  • Symplicity Renal Denervation System
  • Paradise Renal Denervation System
  • Vessix Renal Denervation System
  • Iberis Renal Sympathetic Denervation System
  • Others

On the basis of technology the renal denervation market is segmented into:

  • Micro-infusion
  • Ultrasound
  • Radiofrequency
About the Author

Future Market Insights (Fmi) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature.

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Apurva Deshpande

Apurva Deshpande

Flag of United States
United States

Member since: Jul 04, 2018
Total live articles: 225

Related Articles